FDA rejects EpiCept's marketing application for cancer drug Ceplene

08/23/2010 | Wall Street Journal, The

The FDA denied EpiCept's application to market Ceplene, a drug candidate for acute myeloid leukemia, because of concerns about the treatment's effectiveness. The agency recommended an additional clinical study to verify Ceplene's efficacy when used in combination with anti-cancer agent interleukin-2.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN